Home > Healthcare > Pharmaceuticals > Pharma Manufacturing > In Vivo CRO Market
In Vivo CRO Market size was valued at USD 4.7 billion in 2023 and is expected to exhibit growth of 7.8% from 2024 to 2032. One of the primary drivers is the increasing complexity of drug development process, that has led pharmaceutical and biotechnology companies to outsource these services to specialized CROs.
Additionally, the rising prevalence of chronic diseases and the need for innovative therapies have fueled the demand for in vivo studies, further fueling the market growth. Moreover, stringent regulations for drug approvals have increased the reliance on CROs for conducting preclinical in vivo studies to ensure compliance with regulatory standards. Furthermore, the growing trend of personalized medicine and the development of novel biologics and biosimilars have further propelled the demand for in vivo CRO services, driving market growth.
Report Attribute | Details |
---|---|
Base Year: | 2023 |
In Vivo CRO Market Size in 2023: | USD 4.7 Billion |
Forecast Period: | 2024 to 2032 |
Forecast Period 2024 to 2032 CAGR: | 7.8% |
2032 Value Projection: | USD 9.1 Billion |
Historical Data for: | 2021 – 2023 |
No. of Pages: | 272 |
Tables, Charts & Figures: | 470 |
Segments covered: | Animal Model, Service, Drug Type, Therapeutic Area, End-use, and Region |
Growth Drivers: |
|
Pitfalls & Challenges: |
|
In vivo CRO services refer to the range of research services provided by Contract Research Organizations (CROs) that involve studies conducted on living organisms, typically animals, to assess the safety and efficacy of novel therapeutics. These services often include preclinical studies, such as toxicology, pharmacokinetics, and efficacy studies, conducted to support the development and regulatory approval of new drugs or medical products. In vivo CROs play a crucial role in drug development by providing expertise, facilities, and resources to conduct these studies in compliance with regulatory requirements.